<DOC>
	<DOCNO>NCT00055107</DOCNO>
	<brief_summary>Cryptosporidium parvum ( C. parvum ) parasite cause chronic diarrhea significant problem HIV infect child develop country . C. parvum infection treat drug nitazoxanide ( NTZ ) . However , NTZ test HIV infect child . The purpose study test safety NTZ HIV infect child chronic diarrhea cause C. parvum . Study hypothesis : Twice-daily NTZ safe well tolerate HIV infected infant , child , adolescent chronic diarrhea cause C. parvum infection .</brief_summary>
	<brief_title>Nitazoxanide Treatment Chronic Diarrhea HIV Infected Children</brief_title>
	<detailed_description>C. parvum significant opportunistic infection much develop world , child may access highly active antiretroviral therapy . There currently establish therapy chronic cryptosporidiosis HIV infect child . The FDA approve NTZ treatment cryptosporidiosis diarrhea ; however , data safety effectiveness NTZ HIV infect child . The purpose study evaluate safety different dos NTZ HIV infect child chronic diarrhea cause C. parvum . In Step 1 , participant receive one four different dos NTZ . Participants take NTZ twice day 56 day either liquid pill form . All participant closely monitored drug toxicity . There seven study visit ; occur study entry , Weeks 1 , 2 , 4 , 6 , 8 , Day 70 . Study visit include physical exam blood , urine , stool collection . Pharmacokinetic ( PK ) sample perform four study visit . PK sample require participant take morning NTZ dose clinic ; participant undergo additional blood collection either take NTZ . At end 56-day study period , participant experience positive clinical benefit NTZ harmful side effect may choose continue take NTZ additional 24 week enter Step 2 . Participants continue take NTZ Day 56 follow 2 additional week .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Cryptosporidiosis</mesh_term>
	<mesh_term>Nitazoxanide</mesh_term>
	<criteria>Inclusion Criteria Step 1 : HIV infect Chronic diarrhea 3 bowel movement per day least 5 day 2 week prior study entry OR 2 bowel movement per day least 5 day 2 week prior study entry accompany dehydration Documented presence C. parvum oocysts stool Weight 4.0 kg ( 8.8 lb ) AND less equal maximum weight age group specify study protocol Parent guardian willing provide inform consent , applicable Willing use acceptable form contraception Exclusion Criteria Step 1 : Inability take liquid tablet form medication Serum transaminase ( ALT ) bilirubin great equal 5 time upper limit normal study screen Active M. avium intracellulare cytomegalovirus ( CMV ) colitis Active cancer Certain medication Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Nitazoxanide</keyword>
	<keyword>Antiprotozoal Agents</keyword>
	<keyword>Cryptosporidiosis</keyword>
	<keyword>Cryptosporidium parvum</keyword>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Drug Adminstration Schedule</keyword>
</DOC>